Loading market movers...

Voxzogo

Approved

Vosoritide

BioMarin Pharmaceutical Inc. (BMRN)

00%

Orphan DrugFast TrackBreakthrough TherapyLearn about designations

Approved

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jul '27

BMRNPDUFA$10.6B

Approved✅Approved

FDA PDUFA Date Voxzogo

Voxzogo• Achondroplasia

BTDFTOrphan

Jul 2027~Confirmed

Competitive Landscape

6 competitors in Achondroplasia

ASNDTransCon CNP

ASNDNavepegritide

ASNDPlacebo for Navepegritide

View Full Landscape

Drug Information

Target Indication

Achondroplasia

Mechanism of Action

C-type Natriuretic Peptide Analog

Clinical Trial

Last updated: 12/3/2025

Patent & Exclusivity

ActiveRLD

Latest Patent Expiry

Jul 11, 2042(15y 10m)

Patents Listed

8

Exclusivity

NCENPPODE-387ODE-449

Application

Source: FDA Orange Book

Regulatory Approvals

EMA8/26/2021

Voxzogo

Voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Orphan

Drug Science

Mechanism of action & safety profile

Developer

BMRN

BioMarin Pharmaceutical Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Phenylketonuria

BMN 110 - WeeklyPhase 3

Mucopolysaccharidosis IV A

Valoctocogene roxaparvovecPhase 3

Hemophilia A With Inhibitor

sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterinPhase 3

Phenylketonurias

Phenylketonuria

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts